Mesoblast (NASDAQ:MESO) Cut to Hold at Jefferies Financial Group

Mesoblast (NASDAQ:MESO) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued on Monday, MarketBeat reports.

MESO has been the topic of several other reports. Piper Sandler upped their target price on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Tuesday, September 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. Finally, StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.50.

Mesoblast Trading Down 1.2 %

Shares of NASDAQ:MESO opened at $17.02 on Monday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. Mesoblast has a 12 month low of $1.61 and a 12 month high of $19.15. The stock’s 50 day moving average price is $10.77 and its 200 day moving average price is $8.44.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC boosted its position in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after purchasing an additional 26,959 shares during the period. Marshall Wace LLP bought a new stake in shares of Mesoblast during the 2nd quarter worth $562,000. Lazari Capital Management Inc. grew its stake in Mesoblast by 6.6% in the 2nd quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company’s stock valued at $364,000 after buying an additional 3,300 shares during the last quarter. XY Capital Ltd bought a new position in Mesoblast in the 3rd quarter worth $244,000. Finally, Creative Planning acquired a new position in Mesoblast during the 3rd quarter worth $147,000. 1.43% of the stock is owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.